SC
Therapeutic Areas
Novavax Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Nuvaxovid® (NVX-CoV2373) | COVID-19 (primary series & boosters) | Approved/Commercial |
| Covovax™ | COVID-19 | Approved/Commercial |
| COVID-19-Influenza Combination (CIC) Vaccine | COVID-19 and Seasonal Influenza | Phase 3 |
| Quadrivalent Nanoparticle Influenza Vaccine (qNIV) | Seasonal Influenza | Phase 3 |
| Respiratory Syncytial Virus (RSV) Vaccine (ResVax®) | RSV disease in infants via maternal immunization | Phase 3 |
| Malaria Vaccine (R21/Matrix-M) | Malaria | Phase 3 |
| Omicron-Specific COVID-19 Vaccine | COVID-19 (Omicron variants) | Phase 2/3 |
Leadership Team at Novavax
JC
John C. Jacobs
President & Chief Executive Officer
JF
James F. Young
Chief Research and Development Officer
JA
John A. Herrmann III
Executive Vice President, Chief Legal Officer & Corporate Secretary
FD
Filip Dubovsky
Executive Vice President, Chief Medical Officer
JJ
John J. Trizzino
Executive Vice President, Chief Commercial Officer & Chief Business Officer
JM
John M. Kershner
Senior Vice President, Chief Accounting Officer & Treasurer (Interim Principal Financial Officer)
RH
Richard H. Douglas
Chairman of the Board
MA
Michael A. McManus, Jr.
Director
DM
David M. Mott
Director
GC
Gary C. Evans
Director